Tumor Microenvironment Enriches the Stemness Features: the Architectural Event of Therapy Resistance and Metastasis

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2022 Dec 22

PMID 36550571

Authors

Palanisamy Nallasamy

Rama Krishna Nimmakayala

Seema Parte

Abhirup C Are

Surinder K Batra

Moorthy P Ponnusamy

Affiliations

Soon will be listed here.

Abstract

Cancer divergence has many facets other than being considered a genetic term. It is a tremendous challenge to understand the metastasis and therapy response in cancer biology; however, it postulates the opportunity to explore the possible mechanism in the surrounding tumor environment. Most deadly solid malignancies are distinctly characterized by their tumor microenvironment (TME). TME consists of stromal components such as immune, inflammatory, endothelial, adipocytes, and fibroblast cells. Cancer stem cells (CSCs) or cancer stem-like cells are a small sub-set of the population within cancer cells believed to be a responsible player in the self-renewal, metastasis, and therapy response of cancer cells. The correlation between TME and CSCs remains an enigma in understanding the events of metastasis and therapy resistance in cancer biology. Recent evidence suggests that TME dictates the CSCs maintenance to arbitrate cancer progression and metastasis. The immune, inflammatory, endothelial, adipocyte, and fibroblast cells in the TME release growth factors, cytokines, chemokines, microRNAs, and exosomes that provide cues for the gain and maintenance of CSC features. These intricate cross-talks are fueled to evolve into aggressive, invasive, migratory phenotypes for cancer development. In this review, we have abridged the recent developments in the role of the TME factors in CSC maintenance and how these events influence the transition of tumor progression to further translate into metastasis and therapy resistance in cancer.

Citing Articles

Salicylaldehyde Benzoylhydrazones with Anticancer Activity and Selectivity: Design, Synthesis, and In Vitro Evaluation.

Nikolova-Mladenova B, Mihaylova R, Atanasova M, Zhivkova Z, Doytchinova I Molecules. 2025; 30(5).

PMID: 40076242 PMC: 11901818. DOI: 10.3390/molecules30051015.

A novel stemness-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity of clear cell renal cell carcinoma.

Liu J, Yao L, Yang Y, Ma J, You R, Yu Z J Transl Med. 2025; 23(1):238.

PMID: 40016772 PMC: 11869577. DOI: 10.1186/s12967-025-06251-6.

Significance of Malic Enzyme 1 in Cancer: A Review.

Fujiwara-Tani R, Nakashima C, Ohmori H, Fujii K, Luo Y, Sasaki T Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996805 PMC: 11854147. DOI: 10.3390/cimb47020083.

Adiponectin Influences the Behavior of Stem Cells in Hormone-Resistant Breast Cancer.

Naimo G, Forestiero M, Giordano F, Leonetti A, Gelsomino L, Panno M Cells. 2025; 14(4).

PMID: 39996758 PMC: 11853953. DOI: 10.3390/cells14040286.

gene expression as a prognostic marker for clinical outcomes in lung adenocarcinoma.

Qiu L, Li T, Qing B, Zhao C, Zhang X, Watanabe S Transl Lung Cancer Res. 2025; 14(1):224-238.

PMID: 39958209 PMC: 11826265. DOI: 10.21037/tlcr-24-623.

References

Huang S, Liao W, Hsu C, Chan T, Liao T, Yang P . A Novel Invadopodia-Specific Marker for Invasive and Pro-Metastatic Cancer Stem Cells. Front Oncol. 2021; 11:638311. PMC: 8200852. DOI: 10.3389/fonc.2021.638311. View

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Ye X, Xu S, Xin Y, Yu S, Ping Y, Chen L . Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J Immunol. 2012; 189(1):444-53. DOI: 10.4049/jimmunol.1103248. View

He M, Wu H, Jiang Q, Liu Y, Han L, Yan Y . Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin. Mol Oncol. 2018; 13(2):403-421. PMC: 6360369. DOI: 10.1002/1878-0261.12419. View

Deng J, Shao J, Markowitz J, An G . ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors. Pharm Res. 2014; 31(9):2237-55. DOI: 10.1007/s11095-014-1389-0. View

Kilmister E, Tan S . The Role of the Renin-Angiotensin System in the Cancer Stem Cell Niche. J Histochem Cytochem. 2021; 69(12):835-847. PMC: 8647629. DOI: 10.1369/00221554211026295. View

Clara J, Monge C, Yang Y, Takebe N . Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol. 2019; 17(4):204-232. DOI: 10.1038/s41571-019-0293-2. View

Nurmik M, Ullmann P, Rodriguez F, Haan S, Letellier E . In search of definitions: Cancer-associated fibroblasts and their markers. Int J Cancer. 2019; 146(4):895-905. PMC: 6972582. DOI: 10.1002/ijc.32193. View

Marvel D, Gabrilovich D . Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015; 125(9):3356-64. PMC: 4588239. DOI: 10.1172/JCI80005. View

10.

Raggi C, Mousa H, Correnti M, Sica A, Invernizzi P . Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene. 2015; 35(6):671-82. DOI: 10.1038/onc.2015.132. View

11.

Storci G, Sansone P, Mari S, DUva G, Tavolari S, Guarnieri T . TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. J Cell Physiol. 2010; 225(3):682-91. PMC: 2939957. DOI: 10.1002/jcp.22264. View

12.

Fukushima K, Tsuchiya K, Kano Y, Horita N, Hibiya S, Hayashi R . Atonal homolog 1 protein stabilized by tumor necrosis factor α induces high malignant potential in colon cancer cell line. Cancer Sci. 2015; 106(8):1000-7. PMC: 4556389. DOI: 10.1111/cas.12703. View

13.

Mitra A, Yan J, Xia X, Zhou S, Chen J, Mishra L . IL6-mediated inflammatory loop reprograms normal to epithelial-mesenchymal transition metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta-deficient β2-spectrin mice. Hepatology. 2016; 65(4):1222-1236. PMC: 5360560. DOI: 10.1002/hep.28951. View

14.

Sakemura R, Hefazi M, Siegler E, Cox M, Larson D, Hansen M . Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma. Blood. 2022; 139(26):3708-3721. PMC: 11290597. DOI: 10.1182/blood.2021012811. View

15.

Wei L, Lin Q, Lu Y, Li G, Huang L, Fu Z . Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-β1/SMAD2/3 pathway and ABCC1 transactivation. Cell Death Dis. 2021; 12(4):334. PMC: 8007632. DOI: 10.1038/s41419-021-03574-2. View

16.

Zhao J . Cancer stem cells and chemoresistance: The smartest survives the raid. Pharmacol Ther. 2016; 160:145-58. PMC: 4808328. DOI: 10.1016/j.pharmthera.2016.02.008. View

17.

Liu M, Zang F, Zhang S . RBCK1 contributes to chemoresistance and stemness in colorectal cancer (CRC). Biomed Pharmacother. 2019; 118:109250. DOI: 10.1016/j.biopha.2019.109250. View

18.

Azzoni V, Wicinski J, Macario M, Castagne M, Finetti P, Ambrosova K . BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells. Cell Death Dis. 2022; 13(2):96. PMC: 8811067. DOI: 10.1038/s41419-022-04538-w. View

19.

Nair N, Sanchez Calle A, Zahra M, Prieto-Vila M, Oo A, Hurley L . A cancer stem cell model as the point of origin of cancer-associated fibroblasts in tumor microenvironment. Sci Rep. 2017; 7(1):6838. PMC: 5533745. DOI: 10.1038/s41598-017-07144-5. View

20.

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B . The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull. 2017; 7(3):339-348. PMC: 5651054. DOI: 10.15171/apb.2017.041. View